Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 58 min ago
Peer-reviewedCC BYCancers

The Molecular Landscape of the Senescence-EMT Interplay: Deciphering Tumour Plasticity Through Molecular Signatures and Multi-Omic Profiling.

  • Eva M Verdugo-Sivianes1
  • Carmen Campos-Silva1
  • José Luis García-Márquez2
  • Elena Aguado-Domínguez3
  1. 1Departamento de Biociencias, Facultad de Ciencias de la Salud, Universidad Loyola Andalucía, Avda. de las Universidades S/N, Dos Hermanas, 41704 Sevilla, Spain.
  2. 2Facultad de Ciencias de la Salud, Universidad Loyola Andalucía, Avda. de las Universidades S/N, Dos Hermanas, 41704 Sevilla, Spain.
  3. 3Departamento de Ciencias Clínicas y de la Salud, Facultad de Ciencias de la Salud, Universidad Loyola Andalucía, Avda. de las Universidades S/N, Dos Hermanas, 41704 Sevilla, Spain.
Read full textPDFDOICite

Abstract

Therapy-induced senescence (TIS) is a common response to anticancer treatments, characterised by stable cell cycle arrest and the acquisition of a complex senescence-associated secretory phenotype (SASP). Initially regarded as a beneficial mechanism that limits tumour growth, growing evidence indicates that TIS is a highly dynamic and heterogeneous process with context-dependent effects that can either suppress or promote tumour progression. The SASP is a central mediator of tumour plasticity, linking TIS to epithelial-to-mesenchymal transition (EMT), cancer stemness, microenvironmental remodelling, therapeutic resistance, and metastatic dissemination. These findings highlight the therapeutic potential of senotherapeutic approaches, including senolytic and senomorphic agents, as key components of one-two-punch therapeutic strategies to selectively eliminate or modulate persistent senescent cells and improve treatment outcomes. Recent advances in multi-omics technologies, artificial intelligence, and liquid biopsy are further transforming the study of senescence by enabling comprehensive molecular characterisation, biomarker discovery, patient stratification, and real-time monitoring of tumour evolution. Collectively, current evidence supports a paradigm shift in which senescence should be considered a dynamic regulator of tumour plasticity and a promising target for precision oncology strategies.

Related

  1. Deciphering the prognostic and immunological landscape of NFKBIA across human cancers
    Zhe Guo, Xiaolong Ding, Chenglong Zhang +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  2. The Landscape of Tumor Dissemination in Leptomeningeal Disease: Mapping CTC Plasticity and Regional Heterogeneity Across Blood and CSF Compartments
    Stephanie N. Shishido, Baishali Chaudhuri, Vidur Mushran +7
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Cellular senescence in ovarian cancer: a proposed geroncogenic shift linking aging, plasticity, and therapy resistance
    Yubo Zhang, Yufei Han, Ping Hou +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPhysiologyCrossrefEurope PMC
  4. Multi-omics and pathological landscape of a senescence-associated prognostic model in bladder urothelial carcinoma.
    Suquan Zhong, Yuejun Li, Shanwei Chen +6
    Translational andrology and urologyPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  5. The landscape and plasticity of transposable element expression in an adult stem cell of high physiological and clinical significance.
    Xingyu Fu, Qiangwei Cai, Jingjing Zhao +16
    Cell death discoveryPeer-reviewedCC BYFull textHuman geneticsEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{verdugosivianes2026molecular,
  title = {{The Molecular Landscape of the Senescence-EMT Interplay: Deciphering Tumour Plasticity Through Molecular Signatures and Multi-Omic Profiling.}},
  author = {Eva M Verdugo-Sivianes and Carmen Campos-Silva and José Luis García-Márquez and Elena Aguado-Domínguez},
  journal = {Cancers},
  year = {2026},
  month = oct,
  doi = {10.3390/cancers18193204},
  url = {https://europepmc.org/article/MED/42882898},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - The Molecular Landscape of the Senescence-EMT Interplay: Deciphering Tumour Plasticity Through Molecular Signatures and Multi-Omic Profiling.
AU  - Eva M Verdugo-Sivianes
AU  - Carmen Campos-Silva
AU  - José Luis García-Márquez
AU  - Elena Aguado-Domínguez
PY  - 2026
DA  - 2026/10/04
JO  - Cancers
DO  - 10.3390/cancers18193204
UR  - https://europepmc.org/article/MED/42882898
AB  - Therapy-induced senescence (TIS) is a common response to anticancer treatments, characterised by stable cell cycle arrest and the acquisition of a complex senescence-associated secretory phenotype (SASP). Initially regarded as a beneficial mechanism that limits tumour growth, growing evidence indicates that TIS is a highly dynamic and heterogeneous process with context-dependent effects that can either suppress or promote tumour progression. The SASP is a central mediator of tumour plasticity, linking TIS to epithelial-to-mesenchymal transition (EMT), cancer stemness, microenvironmental remodelling, therapeutic resistance, and metastatic dissemination. These findings highlight the therapeutic potential of senotherapeutic approaches, including senolytic and senomorphic agents, as key components of one-two-punch therapeutic strategies to selectively eliminate or modulate persistent senescent cells and improve treatment outcomes. Recent advances in multi-omics technologies, artificial intelligence, and liquid biopsy are further transforming the study of senescence by enabling comprehensive molecular characterisation, biomarker discovery, patient stratification, and real-time monitoring of tumour evolution. Collectively, current evidence supports a paradigm shift in which senescence should be considered a dynamic regulator of tumour plasticity and a promising target for precision oncology strategies.
SN  - 2072-6694
ER  -